



## Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference

July 31, 2018

SOUTH SAN FRANCISCO, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Christopher Haqq, M.D., Ph.D., the Company's Executive Vice President of Research and Development and Chief Scientific Officer, will participate in a panel discussion at the Canaccord Genuity 38<sup>th</sup> Annual Growth Conference on Thursday, August 9, 2018 at 12:00 p.m. EDT. The conference will be held at the InterContinental Boston Hotel in Boston, MA.

A live audio webcast of the panel discussion will be available by visiting the Investors section of the Atara website. An archived replay of the webcast will be available on the Company's website for 14 days following the panel discussion.

### **About Atara Biotherapeutics, Inc.**

[Atara Biotherapeutics, Inc. \(@Atarabio\)](#) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara's most advanced T-cell immunotherapy in development, tab-ce<sup>l</sup><sup>TM</sup> (tabelecleucel), is being developed for the treatment of patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC). Atara is also developing off-the-shelf, allogeneic ATA188 and autologous ATA190 T-cell immunotherapies using a complementary targeted antigen recognition technology for specific EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS). Atara's clinical pipeline also includes ATA520 targeting Wilms Tumor 1, or WT1, and ATA230 directed against cytomegalovirus, or CMV. The company was founded in 2012 and is headquartered in South San Francisco, California.

### **INVESTOR & MEDIA CONTACTS:**

#### **Investors:**

John Craighead, Atara Biotherapeutics

650-410-3012

[jcraighead@atarabio.com](mailto:jcraighead@atarabio.com)

Steve Klass, Burns McClellan

212-213-0006 x331

[sklass@burnsmc.com](mailto:sklass@burnsmc.com)

#### **Media:**

Robert Flamm, Burns McClellan

212-213-0006 x364

[rflamm@burnsmc.com](mailto:rflamm@burnsmc.com)

 [Primary Logo](#)

Source: Atara Biotherapeutics, Inc.